IINN VS BNOX Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

IINN
10/100

IINN returned -8.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BNOX
10/100

BNOX returned -76.48% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

IINN
64/100

IINN had a bullish sentiment score of 63.94% across Twitter and StockTwits over the last 12 months. It had an average of 2.16 posts, 0.42 comments, and 2.10 likes per day.

BNOX

"Sentiment" not found for BNOX

Technicals

IINN
10/100

IINN receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

BNOX
11/100

BNOX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

IINN
100/100

IINN has missed earnings 0 times in the last 20 quarters.

BNOX
100/100

BNOX has missed earnings 0 times in the last 20 quarters.

Profit

IINN
21/100

Out of the last 18 quarters, IINN has had 3 profitable quarters and has increased their profits year over year on 3 of them.

BNOX
10/100

Out of the last 20 quarters, BNOX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

IINN
40/100

IINN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

BNOX
48/100

BNOX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares Summary

Nasdaq / IINN
Healthcare
Medical - Devices
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

Bionomics Limited American Depository Shares Summary

Nasdaq / BNOX
Healthcare
Biotechnology
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.